Clinical Trials
27
Trial Phases
5 Phases
Drug Approvals
25
Drug Approvals
Ceftezole Sodium for Injection
- Product Name
- 特子社复
- Approval Number
- 国药准字HJ20171115
- Approval Date
- Jul 29, 2022
Cefazedone Sodium for Injection
- Product Name
- 舒美社复
- Approval Number
- 国药准字HJ20171101
- Approval Date
- Jul 29, 2022
Cefazedone Sodium for Injection
- Product Name
- 舒美社复
- Approval Number
- 国药准字HJ20171099
- Approval Date
- Jul 29, 2022
Cefazedone Sodium for Injection
- Product Name
- 舒美社复
- Approval Number
- 国药准字HJ20171102
- Approval Date
- Jul 29, 2022
Ceftezole Sodium for Injection
- Product Name
- 特子社复
- Approval Number
- 国药准字HJ20171118
- Approval Date
- Jul 29, 2022
Ceftezole Sodium for Injection
- Product Name
- 特子社复
- Approval Number
- 国药准字HJ20171117
- Approval Date
- Jul 29, 2022
Cefazedone Sodium for Injection
- Product Name
- 舒美社复
- Approval Number
- 国药准字HJ20171100
- Approval Date
- Jul 29, 2022
Ceftezole Sodium for Injection
- Product Name
- 特子社复
- Approval Number
- 国药准字HJ20171116
- Approval Date
- Jul 29, 2022
Cefmetazole Sodium for Injection
- Product Name
- 注射用头孢美唑钠
- Approval Number
- H20130437
- Approval Date
- Mar 26, 2020
Ceftezole Sodium for Injection
- Product Name
- 特子社复
- Approval Number
- 国药准字J20180052
- Approval Date
- Mar 31, 2018
- Prev
- 1
- 2
- 3
- Next
Clinical Trials
Distribution across different clinical trial phases (27 trials with phase data)• Click on a phase to view related trials
Evaluate the Efficacy and Safety of SPC1001 Low in Patients With Essential Hypertension
- Conditions
- Hypertension (HTN)NYHA Class III Heart FailureNYHA Class IV Heart FailureDiabete Mellitus
- Interventions
- Drug: SPC1001 LowDrug: SPC5002Drug: SPC5003Drug: SPC5004
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT07064525
- Locations
- 🇰🇷
CHA Gangnam Medical Center, CHA University, Seoul, Korea, Republic of
Efficacy and Safety of SPC1001 in Patients With Essential Hypertension
- Conditions
- Hypertension, EssentialCardiovascular DiseasesCardiology
- Interventions
- First Posted Date
- 2025-02-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 252
- Registration Number
- NCT06826872
- Locations
- 🇰🇷
CHA Gangnam Medical Center, CHA University, Seoul, Republic of Korea, Seoul, Korea, Republic of
Efficacy and Safety of SP-8203 (Otaplimastat) in Patients With Acute Ischemic Stroke Receiving Thrombolytic Standard of Care
- First Posted Date
- 2024-10-28
- Last Posted Date
- 2025-03-07
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 852
- Registration Number
- NCT06660719
- Locations
- 🇰🇷
Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Ulsan University Hospital, Ulsan, Korea, Republic of
Pivotal Study to Evaluate Efficacy and Safety of SP5M002 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis
- Conditions
- Osteoarthritis
- First Posted Date
- 2024-05-03
- Last Posted Date
- 2024-05-03
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 297
- Registration Number
- NCT06399042
- Locations
- 🇰🇷
Kyungpook National University Hospital, Daegu, Korea, Republic of
🇰🇷Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Chonnam National University Bitgoeul Hospital, Gwangju, Korea, Republic of
Pivotal Study to Evaluate Efficacy and Safety of SP5M001 Inj. as Compared to Synovian Inj. in Patients With Mild to Moderate Knee Osteoarthritis
- First Posted Date
- 2024-03-13
- Last Posted Date
- 2024-03-13
- Lead Sponsor
- Shin Poong Pharmaceutical Co. Ltd.
- Target Recruit Count
- 223
- Registration Number
- NCT06307847
- Locations
- 🇰🇷
Yeungnam University Medical Center, Daegu, Korea, Republic of
🇰🇷Cheonam National University Hwasun Hospital, Hwasun, Korea, Republic of
🇰🇷Gachon University Gil Medical Center, Incheon, Korea, Republic of
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- Next